CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 350 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
PF-06700841 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03845517
NCT03845517Phase 2Completed
CompareCT.gov

A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Pfizer·interventional·Posted Feb 19, 2019·Updated Sep 5, 2024

In Brief

A Phase 2 clinical trial evaluating Placebo, PF-06700841 15 mg, and 2 other interventions for Systemic Lupus Erythematosus. Completed, enrolled 350 participants across 164 sites in 26 countries.

Detailed Summary

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesArgentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Mexico, Poland, Portugal, Romania, Serbia, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 19, 2019
Enrollment StartApr 18, 2019
Primary CompletionOct 5, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.4 years ago

Interventions

Placebodrug

Placebo

PF-06700841 15 mgdrug

PF-06700841 15 mg

PF-06700841 30 mgdrug

PF-06700841 30 mg

PF-06700841 45 mgdrug

PF-06700841 45 mg